
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is expected to see positive growth in the near future through its ongoing Phase 3 trials and potential for label expansion for its marketed products, as well as its focus on capturing a significant portion of the non-Medicare CKD market. Despite potential risks, the company's strong financial standing and potential billion-dollar peak sales for Ibsrela make it a promising investment opportunity. With analysts' upgraded ratings and a new price target set, the company is poised for success in the biopharmaceutical industry.
Bears say
Ardelyx is steadily advancing its pipeline with its IBSRELA and XPHOZAH drugs, but increasing expenses and potential pull-forward of sales raise concerns about the company's growth potential. Additionally, the company's IP strategy is encouraging, but with a negative outlook on the stock, the potential for success with its Phase 3 ACCEL trial in CIC patients is still uncertain and not factored into the valuation. While the company's target of 110 trial sites for IBSRELA is ambitious, it may not translate to immediate revenue growth.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares